XML 46 R32.htm IDEA: XBRL DOCUMENT v3.24.4
Stock-Based Compensation (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Stock-Based Compensation [Abstract]    
Schedule of Grant-Date Fair Value of Stock Options Granted The following table presents the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted during the three and nine months ended September 30, 2024 and 2023:
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2024   2023   2024   2023 
Exercise price  $1.00 – 1.12   $1.35 – 1.35   $1.00 – 1.12   $1.35 – 1.84 
Risk-free interest rate   5.2 – 5.2%   4.8 – 4.8%   5.2 – 5.2%   4.7 – 4.8%
Expected volatility   93.2 – 104.6%   134.5 – 134.5%   93.2 – 104.6%   122.2 – 136.9%
Expected dividend yield   0%   0%   0%   0%
Expected life of options (in years)   5.0    5.0    5.0    5.0 
The following table presents the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted:
    Year Ended  
    December 31,  
    2023     2022  
Exercise price     $0.85 – 1.84       $1.67 – 2.61  
Risk-free interest rate     4.7 – 5.0%       0.6 – 4.5%  
Expected volatility     98 – 137%       127 – 164%  
Expected dividend yield     0%       0%  
Expected life of options (in years)     5.0       5.0  

 

Schedule of Option Activity The following table summarizes the Company’s option activity for the nine months ended September 30, 2024 (in thousands, except exercise price and contractual life data):
   Number
Outstanding
   Weighted
Average
Exercise
Price per
Share
   Weighted
Average
Remaining
Contractual
Life (Years)
 
Balance as of January 1, 2024   13,843   $2.64    3.7 
Granted   250    1.01    5.0 
Exercised   
-
    
-
    
-
 
Forfeited   (1,724)   4.11    
-
 
Balance as of September 30, 2024   12,369   $2.41    3.1 
Vested and exercisable as of September 30, 2024   8,375   $2.87    2.8 

 

The following table summarizes the Company’s option activity:
Weighted Average Number of Shares (in thousands)  Weighted Average Exercise Price   Contractual Term
(in years)
 
Outstanding as of December 31, 2021            
As previously reported   5,197   $7.68    2.5 
Adjustments (1)   (1,100)   (2.45)   1.4 
As restated   4,097    5.23    3.9 
Granted   6,853    1.38    5.0 
Forfeited   (1,785)   3.17    - 
Outstanding as of December 31, 2022   9,165    3.51    4.2 
Granted   5,340    1.38    5.0 
Forfeited   (662)   4.41    - 
Outstanding as of December 31, 2023   13,843   $2.64    3.7 
                
Vested as of December 31, 2022   6,413   $3.58    4.2 
Vested as of December 31, 2023   8,803   $3.21    3.4 
Schedule of Exercise Price Range The following table summarizes the exercise price range as of September 30, 2024 (in thousands, except exercise price data):
Exercise Price   Outstanding Options   Exercisable Options 
$0.00 – 1.00    105    10 
$1.00 – 2.00    5,348    1,794 
$2.00 – 3.00    5,845    5,500 
$3.00 – 6.00    38    38 
$6.00 – 8.00    683    683 
$8.00 – 12.00    350    350 
      12,369    8,375 
The following table summarizes the exercise price range as of December 31, 2023 (in thousands):
Exercise Price     Outstanding Options     Exercisable Options  
$ 0.00 – 1.00        180        10  
$ 1.00 – 2.00        5,695        1,935  
$ 2.00 – 3.00        6,359        5,318  
$ 3.00 – 5.00        65        65  
$ 5.00 – 7.00        726        713  
$ 7.00 – 12.00        818        762  
          13,843       8,803  
Schedule of Stock-Based Compensation Expense Related to Common Stock Options and Restricted Shares of Common Stock The Company recognized stock-based compensation expense for services in lieu of cash payments to certain consultants, including expenses for both shares issued and stock option awards granted, in the following expense categories of its consolidated statements of operations (in thousands):
  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2024   2023   2024   2023 
Selling and marketing  $
-
   $(107)  $
-
   $(174)
General and administrative   2    107    21    456 
Total stock-based compensation  $2   $
-
   $21   $282 
The Company recognized stock-based compensation expense related to common stock options and restricted shares of common stock in the following expense categories of its consolidated statements of operations (in thousands):
   Year Ended December 31, 
   2023   2022 
Research and development   2,080    509 
Selling and marketing   (279)   494 
General and administrative   2,470    8,320 
Total stock-based compensation  $4,271   $9,323 
Schedule of Stock-Based Compensation Expense Related to Common Stock Options and Restricted Shares of Common Stock The Company recognized stock-based compensation expense related to common stock options and restricted shares of common stock in the following expense categories of its consolidated statements of operations (in thousands):
    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2024     2023     2024     2023  
Research and development   $ 562     $ 408     $ 1,761     $ 1,358  
Selling and marketing     12       85       123       (351 )
General and administrative     189       499       796       2,103  
Total stock-based compensation   $ 763     $ 992     $ 2,680     $ 3,110